Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression.

Sci Rep · 2023 · PMC10504303 · PMID 37714917

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

did not reach statistical significancep = 0.082so close (0.05 < p ≤ 0.1)

Although the reduction in AST/ALT ratio during ADT treatment did not reach statistical significance (p = 0.082), a similar trend was observed in nmCRPC cases, notably the AST/ALT ratio at CRPC diagnosis was significantly higher than at PC diagnosis (p = 0.011).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.